Gilead Sciences (NASDAQ:GILD) Rating Increased to Hold at HSBC

HSBC upgraded shares of Gilead Sciences (NASDAQ:GILD) from a reduce rating to a hold rating in a report published on Wednesday, MarketBeat Ratings reports. They currently have $69.00 price objective on the biopharmaceutical company’s stock.

GILD has been the topic of a number of other reports. Oppenheimer reiterated an outperform rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. Cantor Fitzgerald dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a neutral rating on the stock in a research note on Wednesday, February 7th. Wells Fargo & Company dropped their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an equal weight rating on the stock in a research note on Monday, March 4th. StockNews.com cut shares of Gilead Sciences from a strong-buy rating to a buy rating in a research note on Friday, April 19th. Finally, UBS Group dropped their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a neutral rating on the stock in a research note on Wednesday, April 17th. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Hold and a consensus target price of $84.57.

Gilead Sciences Stock Up 0.1 %

GILD opened at $67.08 on Wednesday. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The stock has a market cap of $83.52 billion, a price-to-earnings ratio of 14.91, a PEG ratio of 0.96 and a beta of 0.19. Gilead Sciences has a twelve month low of $65.90 and a twelve month high of $87.86. The company’s 50-day moving average price is $71.56 and its two-hundred day moving average price is $76.39.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.67 earnings per share. As a group, equities analysts expect that Gilead Sciences will post 5.24 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.59%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the transaction, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Nilsine Partners LLC grew its holdings in Gilead Sciences by 1.1% in the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after acquiring an additional 127 shares during the last quarter. Etesian Wealth Advisors Inc. grew its holdings in Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after acquiring an additional 128 shares during the last quarter. Financial Counselors Inc. grew its holdings in Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after acquiring an additional 128 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Gilead Sciences by 3.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 130 shares during the last quarter. Finally, Institutional & Family Asset Management LLC grew its holdings in Gilead Sciences by 10.3% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 140 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.